Ligand Pharmaceuticals Inc. (LGND) CEO John L. Higgins Sells 9,000 Shares of Stock

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) CEO John L. Higgins sold 9,000 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $157.03, for a total value of $1,413,270.00. Following the transaction, the chief executive officer now directly owns 102,700 shares in the company, valued at $16,126,981. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) traded down $0.04 during midday trading on Friday, hitting $157.14. The company had a trading volume of 144,506 shares, compared to its average volume of 353,949. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.95 and a current ratio of 0.97. Ligand Pharmaceuticals Inc. has a 52-week low of $95.08 and a 52-week high of $170.30. The firm has a market cap of $3,317.36, a P/E ratio of 227.74, a price-to-earnings-growth ratio of 1.68 and a beta of 1.07.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LGND. Carillon Tower Advisers Inc. acquired a new position in shares of Ligand Pharmaceuticals in the 4th quarter valued at $30,730,000. Janus Henderson Group PLC increased its position in shares of Ligand Pharmaceuticals by 26.7% in the 3rd quarter. Janus Henderson Group PLC now owns 754,692 shares of the biotechnology company’s stock valued at $102,751,000 after acquiring an additional 159,201 shares during the period. OppenheimerFunds Inc. increased its position in shares of Ligand Pharmaceuticals by 74.0% in the 4th quarter. OppenheimerFunds Inc. now owns 252,961 shares of the biotechnology company’s stock valued at $34,638,000 after acquiring an additional 107,580 shares during the period. Stifel Financial Corp increased its position in shares of Ligand Pharmaceuticals by 1,447.2% in the 3rd quarter. Stifel Financial Corp now owns 109,124 shares of the biotechnology company’s stock valued at $14,839,000 after acquiring an additional 102,071 shares during the period. Finally, William Blair Investment Management LLC increased its position in shares of Ligand Pharmaceuticals by 8.1% in the 4th quarter. William Blair Investment Management LLC now owns 1,240,071 shares of the biotechnology company’s stock valued at $169,803,000 after acquiring an additional 92,695 shares during the period.

A number of equities analysts have recently issued reports on LGND shares. HC Wainwright set a $169.00 price target on Ligand Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Craig Hallum reaffirmed a “buy” rating and set a $170.00 price target (up from $160.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, November 15th. Finally, Roth Capital set a $158.00 price target on Ligand Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, November 13th. Two analysts have rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Ligand Pharmaceuticals has a consensus rating of “Buy” and an average price target of $150.83.

WARNING: This story was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://stocknewstimes.com/2018/02/17/ligand-pharmaceuticals-inc-lgnd-ceo-john-l-higgins-sells-9000-shares-of-stock.html.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply